Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy

Yingyao Chen; Hengjin Dong; Yan Wei; Yi Yang; Jian Ming; Hao Yu

doi:10.1136/bmj-2022-069963

Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy

BMJ. 2023 Jun 15:381:e069963. doi: 10.1136/bmj-2022-069963.

Authors

Yingyao Chen^{1

2}, Hengjin Dong³, Yan Wei^{4

2}, Yi Yang^{4

2}, Jian Ming^{4

2}, Hao Yu⁵

Affiliations

¹ School of Public Health, Fudan University, Shanghai 200032, China yychen@shmu.edu.cn.
² National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.
³ Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁴ School of Public Health, Fudan University, Shanghai 200032, China.
⁵ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Abstract

Yingyao Chen and colleagues examine what can be learnt from China’s approach to funding expensive high technology medicines with uncertain long term benefit

MeSH terms

China
Health Expenditures
Humans
Immunotherapy
Insurance*
Insurance, Health
Insurance, Health, Reimbursement
Neoplasms* / drug therapy
Technology Assessment, Biomedical